scholarly journals Biologic therapy for advanced breast cancer: recent advances and future directions

2020 ◽  
Vol 20 (9) ◽  
pp. 1009-1024 ◽  
Author(s):  
Paolo Tarantino ◽  
Stefania Morganti ◽  
Giuseppe Curigliano
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Biologic Therapy ◽  
Advanced Breast ◽  
Future Directions ◽  
Recent Advances

scholarly journals Erratum: Management of locally advanced breast cancer—perspectives and future directions

2015 ◽  
Vol 12 (6) ◽  
pp. 312-312 ◽  
Author(s):  
Konstantinos Tryfonidis ◽  
Elzbieta Senkus ◽  
Maria J. Cardoso ◽  
Fatima Cardoso
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Future Directions

scholarly journals Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

2013 ◽  
Vol 7 ◽  
pp. BCBCR.S10071 ◽  
Author(s):  
Denise A. Yardley
Keyword(s):  
Breast Cancer ◽  
Antitumor Activity ◽  
Advanced Breast Cancer ◽  
Mammalian Target Of Rapamycin ◽  
Metastatic Breast ◽  
Mtor Inhibitors ◽  
Chemotherapeutic Agents ◽  
Advanced Breast ◽  
Future Directions ◽  
Multiple Components

Improvements in survival of patients with breast cancer have been attributed to the development of agents that target key components of dysregulated pathways involved in oncogenesis and progression of breast cancer. Aberrant mammalian target of rapamycin (mTOR) activation has been implicated in oncogenesis, angiogenesis, and the development of estrogen independence and resistance to chemotherapy in breast tumors. Several mTOR inhibitors (sirolimus, everolimus, temsirolimus, and ridaforolimus) have demonstrated antitumor activity in breast cancer cells. Combining mTOR inhibitors with endocrine therapies has demonstrated clinical antitumor activity in patients with metastatic breast cancer. In addition, mTOR inhibitor combinations with various targeted biologic agents or cytotoxic chemotherapeutic agents are being examined in more than 40 clinical trials with some early promising results. Combination therapies targeting multiple components of these central signaling pathways may be an optimal treatment strategy for patients with advanced breast cancer.

Endocrine resistance in advanced breast cancer: current evidence and future directions

2012 ◽  
Vol 1 (4) ◽  
pp. 305-314 ◽  
Author(s):  
Carlos H Barrios ◽  
André P Fay ◽  
Marcio Debiasi ◽  
Gustavo Werutsky
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Resistance ◽  
Advanced Breast ◽  
Current Evidence ◽  
Future Directions

Management of locally advanced breast cancer—perspectives and future directions

2015 ◽  
Vol 12 (3) ◽  
pp. 147-162 ◽  
Author(s):  
Konstantinos Tryfonidis ◽  
Elzbieta Senkus ◽  
Maria J. Cardoso ◽  
Fatima Cardoso
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Future Directions
Sign in / Sign up

Export Citation Format

Share Document